Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin, and mitomycin C (FAM)

Nissim Haim, Yoram Cohen, Joseph Honigman, Eliezer Robinson

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Thirty-three evaluable patients with advanced gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and mitomycin C (FAM). Two complete and five partial remissions (21% response rate) were observed. The overall median survival of all 33 patients was 5.9 months. Responding patients had significantly better survival than the non-responders (P<0.02). Analysis of the results according to sex, pretreatment performance status, and the histologic differentiation of the tumor failed to demonstrate that any of these factors influenced therapeutic results. The low response rate to FAM found in this study might be related to the fact that in the majority of the patients (85%) the primary gastric tumor had not been resected. The side-effects of this regimen were moderate. Taking into account the low response rate and the moderate myelotoxicity observed, a more intensive use of these three drugs in combination is suggested.

Original languageEnglish
Pages (from-to)277-280
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Issue number3
StatePublished - 1 Jan 1982
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin, and mitomycin C (FAM)'. Together they form a unique fingerprint.

Cite this